76例头孢哌酮/他唑巴坦不良反应报告分析

中国药物警戒 ›› 2015, Vol. 12 ›› Issue (10): 623-626.

76例头孢哌酮/他唑巴坦不良反应报告分析

钟询龙, 冯霞, 段炼, 叶丽卡, 王若伦

广州医科大学附属第二医院，广东广州 510260

收稿日期:2015-06-25 修回日期:2015-12-07 出版日期:2015-10-08 发布日期:2015-12-07
通讯作者: 王若伦，男，硕士，主任药师，临床药学和医院药学。E-mail：zsdx1985115@163.com
作者简介:钟询龙，男，硕士，药师，临床药学和体内药物分析。
基金资助:
国家自然科学基金资助项目(81403031)。

Analysis of 76 Reports of Adverse Drug Reaction Induced by Cefoperazone/Tazobactam

ZHONG Xun-long, FENG Xia, DUAN Lian, YE Li-ka, WANG Ruo-lun

Second Affiliated Hospital of Guangzhou Medical University, Guangdong Guangzhou 510260, China

Received:2015-06-25 Revised:2015-12-07 Online:2015-10-08 Published:2015-12-07

摘要/Abstract

摘要： 目的探讨头孢哌酮/他唑巴坦药品不良反应(ADR)发生的一般特点与规律，并提出预防对策，为促进临床安全、有效、合理用药提供参考。方法采用回顾性研究方法，对我院2005年1月～2015年5月上报至国家不良反应监测中心的76例头孢哌酮/他唑巴坦ADR报告，从患者年龄、性别、原患疾病、用法用量、ADR发生时间、ADR临床表现等方面进行回顾性统计分析。结果 76例头孢哌酮/他唑巴坦ADR报告中，患者在性别方面无统计学差异(P＞0.05)，而在年龄、原患疾病等方面存在显著差异性(P＜0.01)。ADR发生的时间以30 min内为主(59.21%)。ADR以皮肤及其附件损害最多(55.22%)，其次是全身性损害、血液系统损害等。76例中严重的ADR有7例，主要以过敏性休克和血液系统损害为主。结论临床应严格掌握头孢哌酮/他唑巴坦的适应证及用法用量，加强对头孢哌酮/他唑巴坦的用药监护，告知患者使用该药可能发生的ADR，并做好突发严重ADR的应急处理措施。

关键词: 头孢哌酮/他唑巴坦, 药品不良反应, 合理用药

Abstract: Objective To summarize the characteristics and rules of adverse drug reactions (ADRs) induced by cefoperazone/tazobactam and provide prevention countermeasures for clinical safe, effective and rational use of antimicrobials by analysis of antibacterial-related ADR reports. Methods 76 ADR reports were statistically analyzed from Jan, 2005 to May, 2015 in our hospital to ADR monitoring center. The patient's age, gender, diseases, usage and dosage, ADR occurrence time and clinical manifestations were analyzed retrospectively. Results Among the 76 cases of ADR, the difference in gender aspect was not significant (P ＞0.05). There were statistically significant differences of the age, kinds of diseases(P ＜0.01). Less than 30 minutes after administration were ADR high-incidence period (59.21%). The main side effects were injuries of skin and its appendages (55.22%), and followed by systemic damage and hematological system damage, etc. 76 cases of ADR including 7 reports of serious adverse reactions, allergic shock and hematological system were involved in the most of cases. Conclusion The indication and dosage of cefoperazone/tazobactam should be strictly mastered by clinicians, and the pharmaceutical care of cefoperazone/tazobactam should be strengthened. The medical staff should tell patients potential ADR and prepare the emergency treatment measures for incidentally critical ADR.

Key words: cefoperazone/tazobactam, adverse drug reactions, rational drug use

中图分类号:

钟询龙, 冯霞, 段炼, 叶丽卡, 王若伦. 76例头孢哌酮/他唑巴坦不良反应报告分析[J]. 中国药物警戒, 2015, 12(10): 623-626.

ZHONG Xun-long, FENG Xia, DUAN Lian, YE Li-ka, WANG Ruo-lun. Analysis of 76 Reports of Adverse Drug Reaction Induced by Cefoperazone/Tazobactam [J]. Chinese Journal of Pharmacovigilance, 2015, 12(10): 623-626.

参考文献

[1] 孙向菊, 蒋爱华, 徐娜, 等. 头孢哌酮钠他唑巴坦钠试敏致过敏性休克1例[J]. 中国药物警戒, 2014, 11(5): 312-314.
[2] 郭进, 王瑞琴. 头孢哌酮的不良反应[J]. 中国综合临床, 2002, 18(8): 675-676.
[3] 赵业清, 徐传新. 哌拉西林/他唑巴坦致不良反应23例文献分析[J]. 2014, 25(16):1501-1503.
[4] 周践, 周筱青. 65例亚胺培南/西司他丁药品不良反应分析[J]. 中华医院感染学杂志, 2004, 14(6): 671-673.
[5] 魏敏吉, 赵彩芸, 齐慧敏, 等. 头孢哌酮/舒巴坦(1:1)在健康成年与老年人的药代动力学[J]. 中国临床药理学杂志, 2007, 23(1):28-32.
[6] 廉江平. 注射用头孢哌酮钠他唑巴坦钠人体药代动力学研究[D]. 天津：天津大学, 2008：39-51.
[7] 马瑞蓉, 张慧琳, 魏敏吉, 等. 头孢哌酮/三唑巴坦复方制剂的人体药代动力学研究[J]. 中国抗生素杂志, 2003,28(11):682-687.
[8] 齐慧敏, 魏敏吉, 赵彩芸, 等. 健康老年肾对头孢哌酮/舒巴坦(1:1)药代动力学的影响[J].中国临床药理学杂志, 2007, 23(6):433-436.
[9] 褚志杰, 李珍, 唐世新, 等. RP-HPLC法测定人体液中他唑巴坦浓度及其药动学应用[J]. 药学服务与研究, 2003,3(2):98-101.
[10] 张圣雨, 邢海燕, 姜玲. 等. 慢性肾功能不全患者使用头孢哌酮钠他唑巴坦钠致抽搐6例报道[J]. 安徽医药, 2014,18(11):2193-2195.
[11] 孙冉. 头孢菌素类药物皮试亟待规范化[J]. 中国现代药物应用, 2013, 7(3):125-126.
[12] 李娟, 鄢浩. 第三代头孢菌素类药物不良反应机制及风险规避的探讨[J]. 中国新药杂志, 2010, 19(21): 1932-1935.
[13] Andres E, Zimmer J, Affenberger S, et a1. Idiosyncratic drug-induced agranulocytosis：update of an old disorder[J]. Eur J Intern Med, 2006, 17(8): 529-535.
[14] Bhatt V, Saleem A. Review: Drug-induced neutropenia: pathophysiology，clinical features，and management[J]. Ann Clin Lab Sci, 2004, 34(2): 131-137.
[15] Watts R G, Emanuel P D, Zuckerman KS, et a1. Valproic acid induced cytopenias: evidence of a dose related suppression of hematopoiesis[J]. J Pediat, 1990, 117(3): 495-499.